Precigen, Inc. reported $22M of revenue over the trailing twelve months. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $22M (to Q2 2023). Net income: −$158M, trailing twelve months to Q2 2026. Free cash flow: −$115M, trailing twelve months to Q2 2026. EPS: −$1.04, trailing twelve months to Q2 2026.

PGENPrecigen, Inc.

Healthcare

$7.82+108% 1Y

$7.82

$3.1052 weeks$8.57

PGEN as reported

Precigen, Inc. reported $22M of revenue over the trailing twelve months. 11 reported series are charted on this page, each one as filed.

$22M

Revenue, trailing twelve months · to Q2 2023 · every figure below is as filed, with no scoring applied

Net income: −$158M
Net income · +27% year on year · trailing twelve months to Q2 2026
Free cash flow: −$115M
Free cash flow · +65% year on year · trailing twelve months to Q2 2026
EPS: −$1.04
EPS · +148% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PGEN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$22M	n/a	Q2 2023 · 12 quarters behind
Net income	−$158M	+27%	Q2 2026
EPS	−$1.04	+148%	Q2 2026
Gross margin	81%	n/a	Q2 2018 · 32 quarters behind
Operating margin	−93%	n/a	Q4 2020 · 22 quarters behind
Net margin	−778%	n/a	Q2 2023 · 12 quarters behind
ROE	−790%	n/a	Q2 2026
ROA	−136%	n/a	Q2 2026
ROIC	−65%	n/a	Q4 2020 · 22 quarters behind
Free cash flow	−$115M	+65%	Q2 2026
P/E	10.9	n/a	Q2 2023 · 12 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.